Contribute Try STAT+ Today

There’s a popular theory about the limitations of global pharma companies: For all their skyscrapers and strategy reviews and private jets, they’re simply too knotted up in bureaucracy to realize how many great drugs are gathering dust in their vaults.

Now, the biggest of Big Pharma is out do do something about that. Pfizer, home to nearly 100,000 employees, on Monday announced the launch of a six-person startup to develop new drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • How about they make it a non-profit. That way the bottom line will be saving lives and not shareholder profit.

  • As long as the scientists (and management) of these startups are selected with the same criteria scientists are hired at big pharma companies, nothing revolutionary or innovative will ever come out of them

    • Dear Agbo, you should disclose that you work for the home team. LOL

      As I read that clinical stage drugs are the center of it, the only innovation I see here is just finding others willing to foot the bill of the clinical trials. So, no brains and scientific skills required.
      And the fact that Pfizer is not really interested to invest in them, it suggests there is a good chance that the investors will qualify as fools/suckers

Comments are closed.